Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GCGR | P47871 | 2/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.37 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.37 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.37 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23306974 | 0.91 | ESR1 (0.44) | ESR1ESR2CTSSCTSKMAPT | |
| SCHEMBL27864992 | 0.88 | ESR1 (0.53) | ESR1ESR2CTSSCTSKMAPT | |
| SCHEMBL1921149 | 0.88 | KMT2A (0.44) | ESR1ESR2CTSSCTSKMAPT | |
| SCHEMBL1921150 | 0.88 | KMT2A (0.44) | ESR1ESR2CTSSCTSKMAPT | |
| SCHEMBL28100731 | 0.88 | KMT2A (0.44) | ESR1ESR2CTSSCTSKMAPT | |
| Pyrrolidine SCHEMBL17338894 | 0.82 | ESR1 (0.36) | ESR1ESR2CTSSCTSKMAPT | |
| SCHEMBL5541266 | 0.82 | L3MBTL1 (0.45) | ESR1ESR2MAPTKMT2AMEN1 | |
| SCHEMBL5547216 | 0.79 | CA12 (0.43) | ESR1ESR2MAPTL3MBTL1SLC7A5 | |
| SCHEMBL1918994 | 0.78 | ESR1 (0.48) | ESR1ESR2MAPTKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL2684961 | 0.78 | CA12 (0.43) | ESR1ESR2MAPTL3MBTL1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | disclosed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | disclosed |
| US-20190099391-A1 | Glucagon Antagonists | LIGAND PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-20190099391-A1 | Glucagon Antagonists | LIGAND PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-3153501-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-10076504-B2 | Glucagon antagonists | LIGAND PHARMACEUTICALS, INC. | 2018-09-18 | — | — | US | disclosed |
| EP-2799428-A2 | Glucagon antagonists | Metabasis Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2799428-A2 | Glucagon antagonists | Metabasis Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2326618-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2326618-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| EP-2326618-A1 | GLUCAGON ANTAGONISTS | Metabasis Therapeutics, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010019830-A1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019830-A1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030029-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | ESR1 868/4885ESR2 611/4885CTSS 1974/4885 |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | ESR1 868/4885ESR2 611/4885CTSS 1974/4885 |
| US-20190099391-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | ESR1 762/4885ESR2 636/4885CTSS 1938/4885 |
| US-10076504-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | ESR1 762/4885ESR2 636/4885CTSS 1938/4885 |
| US-11352321-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | ESR1 868/4885ESR2 611/4885CTSS 1974/4885 |
| US-10221130-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | ESR1 762/4885ESR2 636/4885CTSS 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.